Q2 2026 saw 5% revenue growth and strong volume gains, with EBIT stable in core feed segments but impacted by Tech Solutions and IPO costs. Full-year guidance for volumes, revenue, and EBIT was upgraded, reflecting favorable biological conditions and robust operational execution.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.